Sign in
4

Changes in Ownership

Cardiff Oncology, Inc. Filed Acc 0001104659-17-053434

Options or other derivatives

  • Chief Scientific Officer acquired 385,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Erlander Mark Chief Scientific Officer 2017-08-22 Grant or award · Stock Options +385,000 1,110,000 D: show line 1 in the form
Loading xslF345X03/a4.xml…